StemoniX Overview

  • Founded
  • 2014
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 33
Employees
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $59.9M
Latest Deal Amount

StemoniX General Information

Description

Developer of a human-induced cardiac screening platform intended to improve and accelerate the process of neurotoxicity research and drug screening. The company's platform creates new cell-based disease models, and operationalizes custom human iPSC disease models at a large scale for high-throughput screening, enabling scientists to quickly and economically conduct research with improved outcomes in a simplified workflow.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Drug Discovery
Parent Company
Primary Office
  • 13300 67th Avenue North
  • Maple Grove, MN 55311
  • United States
+1 (855) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

StemoniX Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
15. Merger/Acquisition 30-Mar-2021 $59.9M 000.00 000.00 Completed Generating Revenue
14. Later Stage VC 01-Oct-2020 00.000 000.00 0000 Completed Generating Revenue
13. Debt - PPP 10-Apr-2020 00000 000.00 Completed Generating Revenue
12. Early Stage VC (Series B) 23-Oct-2019 000.00 000.00 Completed Generating Revenue
11. Early Stage VC 11-Oct-2019 00.000 000.00 Completed Generating Revenue
10. Early Stage VC 06-Sep-2018 00.000 000.00 Completed Generating Revenue
9. Early Stage VC (Series A) 10-Mar-2017 00.000 00.000 Completed Generating Revenue
8. Seed Round 06-Oct-2016 00.00 00.000 Completed Generating Revenue
7. Accelerator/Incubator 03-Oct-2016 $80K $3.42M Completed Generating Revenue
6. Grant 23-Sep-2016 $80K $3.37M Completed Generating Revenue
To view StemoniX’s complete valuation and funding history, request access »

StemoniX Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of a human-induced cardiac screening platform intended to improve and accelerate the process of neurotoxicity
Biotechnology
Maple Grove, MN
33 As of 2021
000.00
00.00 0000-00-00
000000&0 000.00

00000 00

rehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat c
0000 000000000
Boca Raton, FL
000000000000

00000000

luptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non pro
0000 000000000
Cambridge, United Kingdom
00 As of 0000
000.00
00.00 0000-00-00
0000000000 0 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

StemoniX Competitors (33)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Akron Biotech Private Equity-Backed Boca Raton, FL 000000000000
000000000 Venture Capital-Backed Cambridge, United Kingdom 00 000.00 0000000000 0 000.00
0000000000 0000000 Venture Capital-Backed Mont-Saint-Guibert, Belgium 00 00000 0000000000 0
0000000 Corporation London, Canada 00 000.00 00000000 000.00
00000000 Formerly VC-backed Schlieren, Switzerland 00 000.00 0000 000.00
You’re viewing 5 of 33 competitors. Get the full list »

StemoniX Patents

StemoniX Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2020216980-A1 Method of using human spheroids for drug discovery Pending 02-Feb-2019 00000000000
US-20200400651-A1 Method of using human spheroids for drug discovery Pending 02-Feb-2019 00000000000
US-20190085296-A1 Method of expansion of human pancreas progenitor cells from stem cells using feeder-conditioned media Pending 20-Sep-2017 0000000000
JP-2020532992-A Efficient differentiation of human stem cells into embryonic germ layers Pending 07-Sep-2017 0000000000
EP-3679124-A1 Efficient differentiation of human stem cells to definitive endoderm Pending 07-Sep-2017 C12N5/0677

StemoniX Executive Team (6)

Name Title Board Seat Contact Info
Ryan Gordon Vice President of Business Development & Commercialization
Andrew LaFrence Chief Financial Officer & Chief Operating Officer
You’re viewing 2 of 6 executive team members. Get the full list »

StemoniX Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

StemoniX Former Investors (24)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Alumni Ventures Group Venture Capital Minority 000 0000 000000 0
Brightstone Venture Capital Venture Capital Minority 000 0000 000000 0
Carlson School of Management University 000 0000 000000 0
Catalytic Impact Foundation Not-For-Profit Venture Capital Minority 000 0000 000000 0
Chestnut Street Ventures Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 24 investors. Get the full list »

StemoniX Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 0000000 03-Dec-2019 00000 0000 Drug Discovery 0000 000
To view StemoniX’s complete investments history, request access »